United States - English - NLM (National Library of Medicine)

b. braun medical inc. - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate in 5% dextrose injection is indicated for: - prevention of eclampsia in patients with preeclampsia - treatment of seizures and prevention of recurrent seizures in patients with eclampsia magnesium sulfate in 5% dextrose injection is contraindicated in patients: - with heart block or myocardial damage - in diabetic coma - with myasthenia gravis [see warnings and precautions (5.6)] risk summary magnesium sulfate in 5% dextrose injection is indicated in pregnant women for the prevention of eclampsia in women with preeclampsia and the treatment of seizures and prevention of recurrent seizures in women with eclampsia. fetal, neonatal, and maternal risks are discussed throughout the labeling. clinical considerations labor or delivery: magnesium sulfate in 5% dextrose injection is not approved for the treatment of pre-term labor. administration of magnesium sulfate in 5% dextrose injection to pregnant women longer than 5 to 7 days may lead to hypocalcemia and bone abnormalities in the developing fe

United States - English - NLM (National Library of Medicine)

x-gen pharmaceuticals, inc. - phenytoin sodium (unii: 4182431bjh) (phenytoin - unii:6158tkw0c5) - phenytoin sodium 50 mg in 1 ml - parenteral phenytoin sodium injection is indicated for the control of generalized tonic-clonic status epilepticus, and prevention and treatment of seizures occurring during neurosurgery. parenteral phenytoin should be used only when oral phenytoin administration is not possible. phenytoin is contraindicated in patients with a history of hypersensitivity to phenytoin, its inactive ingredients, or other hydantoins. because of its effect on ventricular automaticity, phenytoin is contraindicated in sinus bradycardia, sino-atrial block, second and third degree a-v block, and patients with adams-stokes syndrome. coadministration of phenytoin is contraindicated with delavirdine due to potential for loss of virologic response and possible resistance to delavirdine or to the class of non-nucleoside reverse transcriptase inhibitors.

United States - English - NLM (National Library of Medicine)

cardinal health - phenytoin sodium (unii: 4182431bjh) (phenytoin - unii:6158tkw0c5) - parenteral phenytoin sodium injection is indicated for the control of generalized tonic-clonic status epilepticus, and prevention and treatment of seizures occurring during neurosurgery.  parenteral phenytoin should be used only when oral phenytoin administration is not possible. phenytoin is contraindicated in patients with a history of hypersensitivity to phenytoin, its inactive ingredients, or other hydantoins. because of its effect on ventricular automaticity, phenytoin is contraindicated in sinus bradycardia, sino-atrial block, second and third degree a-v block, and patients with adams-stokes syndrome. coadministration of phenytoin is contraindicated with delavirdine due to potential for loss of virologic response and possible resistance to delavirdine or to the class of non-nucleoside reverse transcriptase inhibitors.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

johnson & johnson sdn bhd - itraconazole -

United States - English - NLM (National Library of Medicine)

camber pharmaceuticals, inc. - itraconazole (unii: 304nug5gf4) (itraconazole - unii:304nug5gf4) - itraconazole oral solution is indicated for the treatment of oropharyngeal and esophageal candidiasis. (see clinical pharmacology: special populations, warnings, and adverse reactions: post-marketing experience for more information.) congestive heart failure: itraconazole oral solution should not be administered to patients with evidence of ventricular dysfunction such as congestive heart failure (chf) or a history of chf except for the treatment of life-threatening or other serious infections. (see boxed warning, warnings, precautions: drug interactions-calcium channel blockers, adverse reactions: post-marketing experience, and clinical pharmacology: special populations.) drug interactions: coadministration of a number of cyp3a4 substrates are contraindicated with itraconazole. plasma concentrations increase for the following drugs: levaceytlmethadol (levomethadyl), met

United States - English - NLM (National Library of Medicine)

mylan institutional llc - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate in 5% dextrose injection is indicated for: magnesium sulfate in 5% dextrose injection is contraindicated in patients: risk summary magnesium sulfate in 5% dextrose injection is indicated in pregnant women for the prevention of eclampsia in women with preeclampsia and the treatment of seizures and prevention of recurrent seizures in women with eclampsia. fetal, neonatal, and maternal risks are discussed throughout the labeling. clinical considerations labor or delivery: magnesium sulfate in 5% dextrose injection is not approved for the treatment of pre-term labor. administration of magnesium sulfate in 5% dextrose injection to pregnant women longer than 5 to 7 days may lead to hypocalcemia and bone abnormalities in the developing fetus, including skeletal demineralization and osteopenia [see warnings and precautions (5.1)] . the use of intravenous magnesium in pregnant women increases human milk magnesium concentrations only slightly and oral absorption of magnesium by the infant is poor. th

United States - English - NLM (National Library of Medicine)

natco pharma usa llc - itraconazole (unii: 304nug5gf4) (itraconazole - unii:304nug5gf4) - itraconazole oral solution is indicated for the treatment of oropharyngeal and esophageal candidiasis. (see clinical pharmacology: special populations, warnings, and adverse reactions: post-marketing experience for more information.) itraconazole oral solution should not be administered to patients with evidence of ventricular dysfunction such as congestive heart failure (chf) or a history of chf except for the treatment of life-threatening or other serious infections. (see boxed warning, warnings, precautions: drug interactions-calcium channel blockers, adverse reactions: post-marketing experience, and clinical pharmacology: special populations.) coadministration of a number of cyp3a4 substrates are contraindicated with itraconazole. plasma concentrations increase for the following drugs: levaceytlmethadol (levomethadyl), methadone, disopyramide, dofetilide, dronedarone, quinidine, isavuconazole, ergot alkaloids (such as dihydroergotamine, ergometrine (ergonovine), ergotamine, methylergometrine (methylergono

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - itraconazole 10 mg/ml - oral solution - 10 mg/ml - active: itraconazole 10 mg/ml excipient: caramel cherry flavour 654536 cherry flavour 654595 hydrochloric acid hydroxypropyl-beta-cyclodextrin propylene glycol purified water saccharin sodium sodium hydroxide sorbitol - sporanox oral solution is indicated for the: · treatment of oral and/or oesophageal candidiasis in hiv-positive or other immunocompromised patients. · prophylaxis of fungal infections in neutropenic patients.

United States - English - NLM (National Library of Medicine)

precision dose inc. - digoxin (unii: 73k4184t59) (digoxin - unii:73k4184t59) - digoxin 0.05 mg in 1 ml - digoxin oral solution, usp is indicated for the treatment of mild to moderate heart failure. digoxin increases left ventricular ejection fraction and improves heart failure symptoms as evidenced by increased exercise capacity and decreased heart failure-related hospitalizations and emergency care, while having no effect on mortality. where possible, digoxin should be used with a diuretic and an angiotensin-converting enzyme inhibitor, but an optimal order for starting these three drugs cannot be specified. digoxin increases myocardial contractility in pediatric patients with heart failure. digoxin oral solution, usp is indicated for the control of resting ventricular response rate in patients with chronic atrial fibrillation. digoxin should not be used for the treatment of multifocal atrial tachycardia. allergy to digoxin is rare. digoxin is contraindicated in patients with a known hypersensitivity to digoxin or other forms of digitalis. digitalis glycosides, such as digoxin, are contraindicated in ventricula

United States - English - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - propranolol hydrochloride (unii: f8a3652h1v) (propranolol - unii:9y8nxq24vq) - cardiac arrhythmias intravenous administration is usually reserved for life-threatening arrhythmias or those occurring under anesthesia. 1. supraventricular arrhythmias intravenous propranolol is indicated for the short-term treatment of supraventricular tachycardia, including wolff‑parkinson‑white syndrome and thyrotoxicosis, to decrease ventricular rate. use in patients with atrial flutter or atrial fibrillation should be reserved for arrythmias unresponsive to standard therapy or when more prolonged control is required. reversion to normal sinus rhythm has occasionally been observed, predominantly in patients with sinus or atrial tachycardia. 2. ventricular tachycardias with the exception of those induced by catecholamines or digitalis, propranolol is not the drug of first choice. in critical situations when cardioversion techniques or other drugs are not indicated or are not effective, propranolol may be considered. if, after consideration of the risks involved, propranolol is used, it should be given intravenously in low dosage and very slowly, as the failing heart requires some sympathetic drive for maintenance of myocardial tone (see dosage & administration). some patients may respond with complete reversion to normal sinus rhythm, but reduction in ventricular rate is more likely. ventricular arrhythmias do not respond to propranolol as predictably as do the supraventricular arrhythmias. intravenous propranolol is indicated for the treatment of persistent premature ventricular extrasystoles that impair the well‑being of the patient and do not respond to conventional measures. 3. tachyarrhythmias of digitalis intoxication intravenous propranolol is indicated to control ventricular rate in life-threatening digitalis-induced arrhythmias. severe bradycardia may occur (see overdosage). 4. resistant tachyarrhythmias due to excessive catecholamine action during anesthesia intravenous propranolol is indicated to abolish tachyarrhythmias due to excessive catecholamine action during anesthesia when other measures fail. these arrhythmias may arise because of release of endogenous catecholamines or administration of catecholamines. all general inhalation anesthetics produce some degree of myocardial depression. therefore, when propranolol is used to treat arrhythmias during anesthesia, it should be used with extreme caution, usually with constant monitoring of the ecg and central venous pressure (see warnings). propranolol is contraindicated in 1) cardiogenic shock; 2) sinus bradycardia and greater than first-degree block; 3) bronchial asthma; and 4) in patients with known hypersensitivity to propranolol hydrochloride.